Company Overview and News

0
Indiabulls Housing Finance Limited - Record Date

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535789 IBULHSGFIN IDKQY

0
Indiabulls Housing Finance Limited - Updates

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535789 IBULHSGFIN IDKQY

0
Indiabulls Housing Finance Limited - Updates

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535789 IBULHSGFIN IDKQY

0
Indiabulls Housing Finance Limited - Updates

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535789 IBULHSGFIN IDKQY

0
Indiabulls Housing Finance Limited - Updates

2018-07-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535789 IBULHSGFIN IDKQY

0
Indiabulls Housing Finance Limited - Updates

2018-07-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535789 IBULHSGFIN IDKQY

0
Risky lending practices, possible job losses may cause home loan defaults: HDFC

2018-07-05 moneycontrol
Aggressive lending practices and possible job losses may restrict repayment capacity of home loan borrowers, according to country’s largest home financier HDFC.
535789 IBULHSGFIN DHFL 511072 IDKQY HDFC 500010 HDFC

0
ICICI Bank grows home loans to Rs 1.5 lakh cr; average age of borrowers at 35-40 years

2018-07-04 moneycontrol
ICICI Bank will focus on rising affordability of Indians and expand to 500 new locations to grow its mortgage business to Rs 2 lakh crore by March-end 2020.
535789 IBULHSGFIN ICICIBANK 532174 IBN IDKQY HDFC 500010 HDFC SBAZ

3
Broker's call: IB Housing (Buy)

2018-06-27 thehindubusinessline
Our interactions with the management of Indiabulls Housing Finance indicate that: 1) the recent hike in lending rates can help to expand spreads q-o-q (stable y-o-y) despite a rise in funding costs; 2) there is some uptick in premium-end housing; and 3) the competitive environment is stable as large banks/PSUs are focussing on internal/asset-quality issues. On spreads, while wholesale rates have surged, the hike in lending rates and credit rating upgrades are helping; access to low-cost forex borrowing has improved.
535789 IBULHSGFIN IDKQY

3
Indiabulls Housing Finance Limited - Updates

2018-06-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535789 IBULHSGFIN IDKQY

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...